department of neurology
The mission of the Houston Methodist Department of Neurology is to translate advances in basic scientific research into meaningful therapies for diseases of the nervous system, while at the same time providing a rich environment of learning opportunities for practicing health care professionals and the medical practitioners of tomorrow. We are at the forefront of understanding the biochemical, pharmacological, physiological and molecular basis of neurological disorders, and translating this knowledge￼ into effective treatments for neurological diseases like stroke, dementia, epilepsy, Parkinson’s disease, ALS and neuromuscular diseases through.
Our clinical programs like the Eddy Scurlock Stroke Center, the MDA/ALS Center, the Concussion Center and the Nantz National Alzheimer Center, our clinicians work closely with scientists to improve diagnosis and treatment options for neurological diseases. Our clinical researchers also offer clinical trials that are designed to answer specific questions about the safety and/or effectiveness of drugs, devices, other therapies, or new ways of using existing treatments.
The Department of Neurology also offers several educational programs, including Grand Rounds and an ACGME-accredited Neurology Residency Program, and fellowships in Clinical Neurophysiology and Neuromuscular Medicine.
US NEWS: NEUROLOGICAL INSTITUTE RANKED NO. 16 IN THE COUNTRY
Houston Methodist Neurological Institute is ranked #16 in U.S. News and World Report’s 2015 rankings for national hospitals in neurology and neurosurgery, we have reached this level of excellence by combining practiced skills with continuous learning and the cutting-edge research from the Houston Methodist Research Institute.
Breaking New Ground In Neurosciences
Your Connection to the Houston Methodist Neurological Institute. Read more and subscribe >>
Clinical Trial for Mild to Moderate Alzheimer's Disease
Houston Methodist is the only location in Texas offering an investigational therapy that focuses on slowing progression in mild to moderate Alzheimer’s. Learn more>